In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Start-Up Previews, September 2012

Executive Summary

This Month's Profile Group: The Fight Against Fat - Start-Ups Look to Serve A Vast Market With Minimally Invasive Bariatric Devices, features profiles of Aspire Bariatrics, EndoSphere, and Vibrynt. Plus these Start-Ups Across Health Care: Anaxsys Technology, Informed Genomics, Inhibrx, MxBiodevices, and Psyadon Pharmaceuticals.

You may also be interested in...



Aspire Bariatrics Inc.

An ideal minimally invasive bariatric technology should be safe, easily implantable, suitable as a permanent therapy, and allow patients to eat a normal diet. Aspire Bariatrics Inc. thinks its solution fits the bill. With the AspireAssist Aspiration Therapy System, patients have control over their weight loss as they are able, about 20 minutes after a meal, to drain a portion of their stomach contents through an endoscopically implanted tube, thus reducing the number of calories absorbed by the body.

MxBiodevices LLC

Despite the proliferation of advanced wound care products to treat diabetic foot ulcers, ranging from negative-pressure wound therapy to moist wound dressings and antimicrobials to artificial skin and growth factors, there has been minimal impact on clinical outcomes, according to MxBiodevices LLC. The start-up has already completed two human clinical trials of its injectable wound repair scaffold that is injected just under the wound surface to provide a healing structure.

Vibrynt Inc.

Vibrynt Inc.’s adjustable VIBRYNT PREVAIL Implant System is a saline-filled, silicone bladder designed to limit the stomach's ability to expand beyond the size of a small tube, and thus limit food consumption and calorie intake. The permanent implant is placed laparoscopically on the top of but still outside the stomach, and is designed to occupy the space that the stomach would normally expand to as a meal is eaten. Unlike the currently available surgical options, with the Vibrynt system there is no altering of the gastrointestinal anatomy and there are no restrictions on the types of healthy foods patients can eat.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1128165

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel